Breaking News Instant updates and real-time market news.

INZY

Inozyme

$29.11 /

-0.76 (-2.54%)

16:11
09/03/20
09/03
16:11
09/03/20
16:11

Inozyme reports Q2 EPS ($7.57), consensus ($1.41)

Cash, cash equivalents and short-term investments were $63.9 million as of June 30, 2020, as compared to $40.8 million as of March 31, 2020. Total cash, cash equivalents and short-term investments on June 30, 2020 does not include total net proceeds of approximately $116.5 million from the Company's IPO in July 2020. Based on its current plans, the Company expects that its existing cash, cash equivalents and short-term investments, including the proceeds from its July 2020 IPO, will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the second half of 2022. "We have made substantial progress over the past quarter and in July, including completing our upsized initial public offering in July, acquiring additional ENPP1 deficiency program assets, and submitting our first investigational new drug application (IND) for INZ-701 for the treatment of ENPP1 deficiency," said Axel Bolte, MSc, MBA, co-founder, president and chief executive officer of Inozyme Pharma. "FDA has requested final study reports for our ongoing three-month GLP toxicology studies in mice and non-human primates and has placed our planned Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 deficiency in the United States on clinical hold pending submission of the reports. We expect to be able to submit these reports in the fourth quarter of this year and initiate our clinical program, as we had planned, in early 2021."

  • 24

    Jul

INZY Inozyme
$29.11 /

-0.76 (-2.54%)

08/18/20
Fly Intel: Top five analyst initiations
08/18/20 Wedbush
Wedbush bullish on Inozyme, initiates with an Outperform
08/18/20 Wedbush
Inozyme initiated with an Outperform at Wedbush
08/18/20 BofA
Inozyme initiated with a Buy at BofA

TODAY'S FREE FLY STORIES

Periodicals
Robinhood CEO considering offering U.S. retirement accounts, Reuters reports » 18:21
07/25/21
07/25
18:21
07/25/21
18:21
HOOD

Robinhood

/

+

Robinhood Markets is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HOOD Robinhood
/

+

  • 29
    Jul
HOOD Robinhood
/

+

HOOD Robinhood
/

+

Periodicals
Tesla solar division asks employees to scour social media for complaints, BI says » 17:52
07/25/21
07/25
17:52
07/25/21
17:52
TSLA

Tesla

$643.27 /

-5.86 (-0.90%)

Tesla's solar-power…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TSLA Tesla
$643.27 /

-5.86 (-0.90%)

TSLA Tesla
$643.27 /

-5.86 (-0.90%)

07/22/21 Credit Suisse
Credit Suisse ahead of consensus into Q2 EPS for Tesla
07/22/21 Barclays
Barclays sees earnings beat for Tesla but remains 'stubbornly' bearish
07/16/21 BofA
Tesla price target raised to $750 from $700 at BofA
07/15/21 Morgan Stanley
Morgan Stanley 'not convinced' Tesla won't get into eVTOL market
TSLA Tesla
$643.27 /

-5.86 (-0.90%)

TSLA Tesla
$643.27 /

-5.86 (-0.90%)

TSLA Tesla
$643.27 /

-5.86 (-0.90%)

TSLA Tesla
$643.27 /

-5.86 (-0.90%)

Initiation
Integral Ad Science initiated with an Outperform at Evercore ISI » 17:46
07/25/21
07/25
17:46
07/25/21
17:46
IAS

Integral Ad Science

$18.89 /

+0.19 (+1.02%)

Evercore ISI analyst Mark…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
  • 30
    Jun
IAS Integral Ad Science
$18.89 /

+0.19 (+1.02%)

Upgrade
HP Enterprise upgraded to Outperform from In Line at Evercore ISI » 17:44
07/25/21
07/25
17:44
07/25/21
17:44
HPE

HP Enterprise

$14.10 /

+0.08 (+0.57%)

, ORCL

Oracle

$87.68 /

-3.02 (-3.33%)

Evercore ISI analyst Amit…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HPE HP Enterprise
$14.10 /

+0.08 (+0.57%)

ORCL Oracle
$87.68 /

-3.02 (-3.33%)

HPE HP Enterprise
$14.10 /

+0.08 (+0.57%)

07/13/21 Evercore ISI
CDW added to Tactical Outperform list at Evercore ISI
07/02/21 Jefferies
HP Enterprise's Zerto deal shows solid execution of M&A playbook, says Jefferies
06/02/21 Loop Capital
HP Enterprise price target raised to $15 from $11 at Loop Capital
06/02/21 Stifel
HP Enterprise guidance reflects supply constraints, says Stifel
ORCL Oracle
$87.68 /

-3.02 (-3.33%)

07/22/21 KeyBanc
Oracle price target raised to $100 from $90 at KeyBanc
06/16/21 Morgan Stanley
Oracle shares likely range-bound until visibility improves, says Morgan Stanley
06/16/21 Jefferies
Oracle price target raised to $80 from $75 at Jefferies
06/16/21 Monness Crespi
Monness Crespi would be buyers of Oracle on any post-earnings weakness
HPE HP Enterprise
$14.10 /

+0.08 (+0.57%)

ORCL Oracle
$87.68 /

-3.02 (-3.33%)

HPE HP Enterprise
$14.10 /

+0.08 (+0.57%)

ORCL Oracle
$87.68 /

-3.02 (-3.33%)

HPE HP Enterprise
$14.10 /

+0.08 (+0.57%)

ORCL Oracle
$87.68 /

-3.02 (-3.33%)

HPE HP Enterprise
$14.10 /

+0.08 (+0.57%)

ORCL Oracle
$87.68 /

-3.02 (-3.33%)

Periodicals
RBC Bearings nears $3B deal for ABB's Dodge unit, Bloomberg reports » 17:10
07/25/21
07/25
17:10
07/25/21
17:10
ROLL

RBC Bearings

$205.99 /

+5.51 (+2.75%)

, ABB

ABB

$36.70 /

+0.7 (+1.94%)

RBC Bearings (ROLL) is in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ABB ABB
$36.70 /

+0.7 (+1.94%)

ROLL RBC Bearings
$205.99 /

+5.51 (+2.75%)

02/02/21 Truist
RBC Bearings price target raised to $140 from $118 at Truist
01/11/21 Truist
RBC Bearings upgraded to Hold from Sell at Truist
08/10/20 Alembic Global
RBC Bearings upgraded to Overweight from Neutral at Alembic Global
ABB ABB
$36.70 /

+0.7 (+1.94%)

07/23/21 UBS
ABB price target raised to CHF 36 from CHF 33 at UBS
07/23/21 JPMorgan
ABB price target raised to CHF 31 from CHF 28 at JPMorgan
07/23/21 Barclays
ABB price target raised to CHF 31 from CHF 29 at Barclays
07/23/21 Morgan Stanley
ABB price target raised to CHF 27.50 from CHF 26.40 at Morgan Stanley
ROLL RBC Bearings
$205.99 /

+5.51 (+2.75%)

ABB ABB
$36.70 /

+0.7 (+1.94%)

Periodicals
Credit Suisse settles spying case with former star banker, Reuters reports » 17:01
07/25/21
07/25
17:01
07/25/21
17:01
CS

Credit Suisse

$10.06 /

+0.09 (+0.90%)

Credit Suisse has reached…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CS Credit Suisse
$10.06 /

+0.09 (+0.90%)

CS Credit Suisse
$10.06 /

+0.09 (+0.90%)

07/19/21 Barclays
Credit Suisse price target lowered to CHF 12 from CHF 12.50 at Barclays
07/15/21 Jefferies
Credit Suisse initiated with a Hold at Jefferies
07/13/21 Deutsche Bank
Credit Suisse price target lowered to CHF 11 from CHF 12 at Deutsche Bank
07/12/21 Morgan Stanley
Credit Suisse price target lowered to CHF 10 from CHF 11 at Morgan Stanley
CS Credit Suisse
$10.06 /

+0.09 (+0.90%)

CS Credit Suisse
$10.06 /

+0.09 (+0.90%)

CS Credit Suisse
$10.06 /

+0.09 (+0.90%)

CS Credit Suisse
$10.06 /

+0.09 (+0.90%)

Periodicals
Canadian union Unifor starts strike at Rio Tinto operations, Reuters says » 16:59
07/25/21
07/25
16:59
07/25/21
16:59
RIO

Rio Tinto

$82.78 /

+0.68 (+0.83%)

Canadian union Unifor…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RIO Rio Tinto
$82.78 /

+0.68 (+0.83%)

RIO Rio Tinto
$82.78 /

+0.68 (+0.83%)

07/20/21 Morgan Stanley
Rio Tinto price target lowered to 6,500 GBp from 6,600 GBp at Morgan Stanley
07/20/21 RBC Capital
Rio Tinto price target lowered to 5,800 GBp from 5,900 GBp at RBC Capital
07/19/21 JPMorgan
Rio Tinto price target lowered to 8,250 GBp from 8,310 GBp at JPMorgan
07/16/21 Goldman Sachs
Rio Tinto upgraded to Buy from Neutral at Goldman Sachs
RIO Rio Tinto
$82.78 /

+0.68 (+0.83%)

RIO Rio Tinto
$82.78 /

+0.68 (+0.83%)

Periodicals
GM, Cruise sue Ford to block use of 'BlueCruise' name, Reuters reports » 16:57
07/25/21
07/25
16:57
07/25/21
16:57
GM

General Motors

$54.95 /

-0.68 (-1.22%)

, F

Ford

$13.81 /

-0.1 (-0.72%)

General Motors (GM) and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GM General Motors
$54.95 /

-0.68 (-1.22%)

F Ford
$13.81 /

-0.1 (-0.72%)

GM General Motors
$54.95 /

-0.68 (-1.22%)

07/16/21 BofA
General Motors price target raised to $90 from $80 at BofA
07/09/21
Fly Intel: Top five analyst initiations
07/08/21 Wedbush
Wedbush starts General Motors at Outperform amid EV 'renaissance'
07/08/21 Wedbush
General Motors initiated with an Outperform at Wedbush
F Ford
$13.81 /

-0.1 (-0.72%)

07/16/21 BofA
Ford price target raised to $18 from $17 at BofA
06/29/21 UBS
Ford price target raised to $16 from $13 at UBS
06/22/21 Barclays
Ford price target raised to $17 from $15 at Barclays
06/04/21 JPMorgan
Ford price target raised to $18 from $16 at JPMorgan
GM General Motors
$54.95 /

-0.68 (-1.22%)

F Ford
$13.81 /

-0.1 (-0.72%)

GM General Motors
$54.95 /

-0.68 (-1.22%)

F Ford
$13.81 /

-0.1 (-0.72%)

GM General Motors
$54.95 /

-0.68 (-1.22%)

F Ford
$13.81 /

-0.1 (-0.72%)

GM General Motors
$54.95 /

-0.68 (-1.22%)

F Ford
$13.81 /

-0.1 (-0.72%)

Periodicals
China regulator bars Tencent from exclusive rights in online music, Reuters says » 16:54
07/25/21
07/25
16:54
07/25/21
16:54
TCEHY

Tencent

$66.89 /

-2.75 (-3.95%)

, TME

Tencent Music

$10.77 /

-0.815 (-7.03%)

China's market…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TCEHY Tencent
$66.89 /

-2.75 (-3.95%)

TME Tencent Music
$10.77 /

-0.815 (-7.03%)

TCEHY Tencent
$66.89 /

-2.75 (-3.95%)

07/13/21 China Renaissance
Tencent assumed with a Buy at China Renaissance
07/13/21 Arete
Tencent downgraded to Neutral on China regulatory risk at Arete
07/13/21 Arete
Tencent downgraded to Neutral from Buy at Arete
05/10/21 Macquarie
Agora price target lowered to $60 from $80 at Macquarie
TME Tencent Music
$10.77 /

-0.815 (-7.03%)

07/16/21 Morgan Stanley
Tencent Music downgraded on peaking industry revenue at Morgan Stanley
07/15/21 Morgan Stanley
Tencent Music downgraded to Equal Weight from Overweight at Morgan Stanley
07/13/21 China Renaissance
Tencent Music assumed with a Buy at China Renaissance
07/08/21 HSBC
Tencent Music price target lowered to $22 from $26 at HSBC
TME Tencent Music
$10.77 /

-0.815 (-7.03%)

  • 26
    Mar
  • 26
    Mar
TCEHY Tencent
$66.89 /

-2.75 (-3.95%)

TME Tencent Music
$10.77 /

-0.815 (-7.03%)

TCEHY Tencent
$66.89 /

-2.75 (-3.95%)

TME Tencent Music
$10.77 /

-0.815 (-7.03%)

TME Tencent Music
$10.77 /

-0.815 (-7.03%)

Periodicals
India plant likely if Tesla succeeds in importing cars, Bloomberg reports » 16:45
07/25/21
07/25
16:45
07/25/21
16:45
TSLA

Tesla

$643.27 /

-5.86 (-0.90%)

A Tesla factory to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TSLA Tesla
$643.27 /

-5.86 (-0.90%)

TSLA Tesla
$643.27 /

-5.86 (-0.90%)

07/22/21 Credit Suisse
Credit Suisse ahead of consensus into Q2 EPS for Tesla
07/22/21 Barclays
Barclays sees earnings beat for Tesla but remains 'stubbornly' bearish
07/16/21 BofA
Tesla price target raised to $750 from $700 at BofA
07/15/21 Morgan Stanley
Morgan Stanley 'not convinced' Tesla won't get into eVTOL market
TSLA Tesla
$643.27 /

-5.86 (-0.90%)

TSLA Tesla
$643.27 /

-5.86 (-0.90%)

TSLA Tesla
$643.27 /

-5.86 (-0.90%)

TSLA Tesla
$643.27 /

-5.86 (-0.90%)

Conference/Events
Jefferies software/Internet analyst to hold analyst/industry conference call » 16:42
07/25/21
07/25
16:42
07/25/21
16:42

Software & Internet…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Conference/Events
Morgan Stanley strategists to hold analyst/industry conference call » 16:38
07/25/21
07/25
16:38
07/25/21
16:38

Co-Head Americas Equity…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

On The Fly
Box Office Battle: 'Old' wins weekend with $16.5M debut » 16:38
07/25/21
07/25
16:38
07/25/21
16:38
T

AT&T

$28.14 /

+0.14 (+0.50%)

, CMCSA

Comcast

$58.36 /

+0.58 (+1.00%)

, CMCSK

Comcast

$58.00 /

+ (+0.00%)

, SONY

Sony

$100.66 /

+1.16 (+1.17%)

, LGF.A

Lionsgate

$15.38 /

-0.3 (-1.91%)

, LGF.B

Lionsgate

$13.62 /

-0.32 (-2.30%)

, DIS

Disney

$176.13 /

+0.995 (+0.57%)

, VIACA

ViacomCBS

$44.71 /

+0.3 (+0.68%)

, VIAC

ViacomCBS

$40.99 /

+0.11 (+0.27%)

"Box Office Battle" is…

ShowHide Related Items >><<
T AT&T
$28.14 /

+0.14 (+0.50%)

CMCSA Comcast
$58.36 /

+0.58 (+1.00%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

SONY Sony
$100.66 /

+1.16 (+1.17%)

LGF.A Lionsgate
$15.38 /

-0.3 (-1.91%)

LGF.B Lionsgate
$13.62 /

-0.32 (-2.30%)

DIS Disney
$176.13 /

+0.995 (+0.57%)

VIACA ViacomCBS
$44.71 /

+0.3 (+0.68%)

VIAC ViacomCBS
$40.99 /

+0.11 (+0.27%)

T AT&T
$28.14 /

+0.14 (+0.50%)

07/22/21 RBC Capital
RBC Capital transfers coverage of AT&T with Sector Perform
07/19/21 MoffettNathanson
New pact with AT&T 'a windfall' for Dish, says MoffettNathanson
07/12/21 Bernstein
Charter downgraded to Market Perform from Outperform at Bernstein
07/09/21 Tigress Financial
AT&T shares have upside to $36 over next year, says Tigress Financial
CMCSA Comcast
$58.36 /

+0.58 (+1.00%)

07/12/21 Benchmark
Comcast price target raised to $72 at Benchmark, sees Olympics boost for Peacock
07/09/21 Raymond James
Comcast price target raised to $65 from $63 at Raymond James
07/02/21 Craig-Hallum
Craig-Hallum says Magnite SpringServe deal more consequential than price implies
06/29/21 Morgan Stanley
Comcast price target raised to $70 from $65 at Morgan Stanley
CMCSK Comcast
$58.00 /

+ (+0.00%)

02/23/21 Credit Suisse
SeaWorld price target raised to $52 from $34 at Credit Suisse
10/07/20 Benchmark
Benchmark would be 'aggressive buyer' of Comcast amid broader market weakness
09/22/20 Benchmark
Comcast price target raised to $60 from $54 at Benchmark
09/16/20 Pivotal Research
Comcast price target raised to $60 from $52 at Pivotal Research
SONY Sony
$100.66 /

+1.16 (+1.17%)

LGF.A Lionsgate
$15.38 /

-0.3 (-1.91%)

07/22/21 Deutsche Bank
Lionsgate downgraded to Hold from Buy at Deutsche Bank
06/04/21 Barrington
Lionsgate price target raised to $27 from $16 at Barrington
06/01/21 Cowen
Lionsgate price target raised to $23 from $20 at Cowen
05/28/21 RBC Capital
Lionsgate price target raised to $17 from $13 at RBC Capital
LGF.B Lionsgate
$13.62 /

-0.32 (-2.30%)

06/01/21 Cowen
Lionsgate price target raised to $23 from $20 at Cowen
05/28/21 RBC Capital
Lionsgate price target raised to $17 from $13 at RBC Capital
05/26/21 Truist
Amazon's MGM deal 'a very modest negative' for Netflix/Disney, says Truist
05/26/21 Loop Capital
Lionsgate price target raised to $21 from $16 at Loop Capital
DIS Disney
$176.13 /

+0.995 (+0.57%)

07/14/21 Tigress Financial
Disney shares can hit $227 within 12 months, says Tigress Financial
07/13/21 KeyBanc
D2C video services best positioned to capture industry economics, says KeyBanc
06/29/21 MoffettNathanson
Netflix needs ad-supported tier or live sports, says MoffettNathanson
06/23/21 Needham
Netflix stance on ads 'materially value-destructive,' says Needham
VIACA ViacomCBS
$44.71 /

+0.3 (+0.68%)

01/05/21 Gabelli
ViacomCBS named a best idea for 2021 at Gabelli
VIAC ViacomCBS
$40.99 /

+0.11 (+0.27%)

06/24/21 BofA
Comcast not pressured to make any imminent acquisition, says BofA
05/24/21 Truist
Lionsgate price target raised to $19 from $15 at Truist
05/21/21 Citi
ViacomCBS price target lowered to $54 from $56 at Citi
05/20/21
Fly Intel: Top five analyst upgrades
T AT&T
$28.14 /

+0.14 (+0.50%)

CMCSA Comcast
$58.36 /

+0.58 (+1.00%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

SONY Sony
$100.66 /

+1.16 (+1.17%)

LGF.A Lionsgate
$15.38 /

-0.3 (-1.91%)

LGF.B Lionsgate
$13.62 /

-0.32 (-2.30%)

DIS Disney
$176.13 /

+0.995 (+0.57%)

VIACA ViacomCBS
$44.71 /

+0.3 (+0.68%)

VIAC ViacomCBS
$40.99 /

+0.11 (+0.27%)

  • 06
    Apr
  • 29
    Mar
  • 24
    Mar
T AT&T
$28.14 /

+0.14 (+0.50%)

CMCSA Comcast
$58.36 /

+0.58 (+1.00%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

SONY Sony
$100.66 /

+1.16 (+1.17%)

DIS Disney
$176.13 /

+0.995 (+0.57%)

VIACA ViacomCBS
$44.71 /

+0.3 (+0.68%)

VIAC ViacomCBS
$40.99 /

+0.11 (+0.27%)

T AT&T
$28.14 /

+0.14 (+0.50%)

CMCSA Comcast
$58.36 /

+0.58 (+1.00%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

SONY Sony
$100.66 /

+1.16 (+1.17%)

LGF.A Lionsgate
$15.38 /

-0.3 (-1.91%)

LGF.B Lionsgate
$13.62 /

-0.32 (-2.30%)

DIS Disney
$176.13 /

+0.995 (+0.57%)

VIACA ViacomCBS
$44.71 /

+0.3 (+0.68%)

VIAC ViacomCBS
$40.99 /

+0.11 (+0.27%)

T AT&T
$28.14 /

+0.14 (+0.50%)

CMCSA Comcast
$58.36 /

+0.58 (+1.00%)

SONY Sony
$100.66 /

+1.16 (+1.17%)

DIS Disney
$176.13 /

+0.995 (+0.57%)

VIAC ViacomCBS
$40.99 /

+0.11 (+0.27%)

Hot Stocks
Allergan announces full results from Phase 3 GEMINI 1 clinical study » 15:55
07/25/21
07/25
15:55
07/25/21
15:55
ABBV

AbbVie

$118.20 /

+0.69 (+0.59%)

Allergan, an AbbVie…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABBV AbbVie
$118.20 /

+0.69 (+0.59%)

ABBV AbbVie
$118.20 /

+0.69 (+0.59%)

07/02/21
Fly Intel: Top five analyst initiations
07/02/21 Daiwa
AbbVie initiated with an Outperform at Daiwa
06/30/21 Piper Sandler
Piper reiterates Overweight rating on Alpine following Merck collaboration
06/25/21 Piper Sandler
FDA won't meet PDUFA target dates for AbbVie's Rinvoq, says Piper Sandler
ABBV AbbVie
$118.20 /

+0.69 (+0.59%)

ABBV AbbVie
$118.20 /

+0.69 (+0.59%)

ABBV AbbVie
$118.20 /

+0.69 (+0.59%)

ABBV AbbVie
$118.20 /

+0.69 (+0.59%)

Hot Stocks
Denali Therapeutics announces interim data from Phase 1/2 study with ETV:IDS » 15:52
07/25/21
07/25
15:52
07/25/21
15:52
DNLI

Denali Therapeutics

$63.89 /

-0.65 (-1.01%)

Denali Therapeutics has…

Denali Therapeutics has announced additional interim data from a Phase 1/2 study evaluating ETV:IDS, an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system and peripheral manifestations of Hunter syndrome. The interim results being presented at MPS 2021, the 16th International Symposium on MPS and Related Diseases, include safety data up to Weeks 43 and 25 from Cohorts A and B, respectively, 6-month biomarker data from Cohort A and up to 3-month biomarker data from Cohort B. This interim analysis of the Phase 1/2 study included data on five patients enrolled in Cohort A and 12 patients enrolled in Cohort B. All patients have neuronopathic MPS II disease except for one patient with non-neuronopathic MPS II disease in Cohort B. The median age of patients is 6 years in both cohorts, with the youngest patients aged 5 and 2 in Cohorts A and B, respectively. All patients received weekly intravenous doses of DNL310 after switching from idursulfase enzyme replacement therapy on Day 1 of the study. Data being presented include safety data up to Weeks 43 and 25 from Cohorts A and B, respectively; 6-month and up to 3-month biomarker data from Cohorts A and B, respectively; and exploratory clinical Global Impression of Change data from Cohort A up to Week 24. Results across Cohorts A and B showed that, following the switch from idursulfase to DNL310, the levels of heparan sulfate in cerebrospinal fluid normalized in all patients analyzed, with rapid response observed in most patients by Week 7, which is consistent with crossing of the BBB by DNL310 and activity in tissues of the CNS. Rapid normalization of CSF heparan sulfate at low dose regimens suggest that BBB crossing with Denali's Transport Vehicle was robust and efficient. Furthermore, the observed decline in urine and serum heparan sulfate was consistent with improved peripheral activity with DNL310. Exploratory clinical data suggest improved clinical symptoms and function for all five patients enrolled in Cohort A as reported by investigators and parents. Based on Global Impression of Change scales, which are standardized assessment scales used to measure change, the data showed clinical improvement in overall MPS II symptoms, cognitive abilities, behavior, and physical abilities. Exploratory lysosomal lipid data showed reductions, which are consistent with improved lysosomal function: 10 of 15 patients across Cohorts A and B had normal GM3 ganglioside levels, including patients on low dose regimens and with shorter duration of treatment. In addition, reductions in levels of bis-phosphate and a potential reduction in levels of glucosylceramide were observed in Cohort A at Week 24. High within patient variability in levels of neurofilament, an exploratory biomarker of neuronal structure, was observed pre- and post-treatment. Data from an ongoing observational natural history study conducted by Denali showed a marked increase in mean levels of serum Nf-L over a 4.5- to 6-month period in patients who subsequently enrolled in Cohort A of the Phase 1/2 study. During the 6-month treatment period of the Phase 1/2 study, mean levels of serum and CSF Nf-L in Cohort A showed a modest increase. Denali believes that the utility of Nf-L as a treatment response biomarker in MPS II will require further investigation. The safety profile of DNL310 remained consistent with standard of care enzyme replacement therapy. DNL310 was generally well tolerated with the most common treatment-emergent adverse events being infusion-related reactions. A total of 3 serious adverse events were reported: 1 previously reported SAE for a patient enrolled in Cohort A based on a mild IRR, and 2 SAEs in a patient enrolled in Cohort B based on severe IRRs. The SAEs resolved, and both patients are continuing in the study. All other treatment-emergent adverse events were mild or moderate. The study continues without modification following recommendation by an independent data monitoring committee on July 9, 2021.

ShowHide Related Items >><<
DNLI Denali Therapeutics
$63.89 /

-0.65 (-1.01%)

DNLI Denali Therapeutics
$63.89 /

-0.65 (-1.01%)

05/18/21 UBS
Denali Therapeutics initiated with a Buy at UBS
02/26/21 H.C. Wainwright
Denali Therapeutics price target raised to $95 from $80 at H.C. Wainwright
02/10/21
Fly Intel: Top five analyst upgrades
02/10/21 Cantor Fitzgerald
Denali Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
DNLI Denali Therapeutics
$63.89 /

-0.65 (-1.01%)

DNLI Denali Therapeutics
$63.89 /

-0.65 (-1.01%)

Conference/Events
Deutsche Bank to hold a fixed income investor conference call » 15:45
07/25/21
07/25
15:45
07/25/21
15:45
DB

Deutsche Bank

$12.44 /

+0.165 (+1.34%)

Management holds a 2Q21…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DB Deutsche Bank
$12.44 /

+0.165 (+1.34%)

DB Deutsche Bank
$12.44 /

+0.165 (+1.34%)

07/09/21
Fly Intel: Top five analyst upgrades
07/09/21 RBC Capital
Deutsche Bank upgraded to Sector Perform from Underperform at RBC Capital
06/30/21 Oddo BHF
Deutsche Bank downgraded to Underperform from Reduce at Oddo BHF
06/16/21 JPMorgan
Deutsche Bank price target raised to EUR 13 from EUR 11 at JPMorgan
DB Deutsche Bank
$12.44 /

+0.165 (+1.34%)

DB Deutsche Bank
$12.44 /

+0.165 (+1.34%)

DB Deutsche Bank
$12.44 /

+0.165 (+1.34%)

DB Deutsche Bank
$12.44 /

+0.165 (+1.34%)

Conference/Events
Citi to hold a fixed income investor review conference call » 15:39
07/25/21
07/25
15:39
07/25/21
15:39
C

Citi

$66.71 /

-0.21 (-0.31%)

CFO Mason and Treasurer…

CFO Mason and Treasurer Verdeschi will hold the 2Q21 Fixed Income Investor Review Conference Call to be held on July 30 at 1 pm. Webcast Link

ShowHide Related Items >><<
C Citi
$66.71 /

-0.21 (-0.31%)

C Citi
$66.71 /

-0.21 (-0.31%)

07/15/21 Piper Sandler
Citi price target lowered to $91 from $95 at Piper Sandler
07/06/21 Keefe Bruyette
Citi assumed with an Outperform at Keefe Bruyette
06/29/21 Evercore ISI
Evercore says Morgan Stanley the 'standout' on capital plan among DFAST banks
06/08/21 Wells Fargo
Citi price target raised to $95 from $88 at Wells Fargo
C Citi
$66.71 /

-0.21 (-0.31%)

C Citi
$66.71 /

-0.21 (-0.31%)

C Citi
$66.71 /

-0.21 (-0.31%)

C Citi
$66.71 /

-0.21 (-0.31%)

Recommendations
Jefferies ups Microsoft price target to $335 ahead of quarterly results » 15:35
07/25/21
07/25
15:35
07/25/21
15:35
MSFT

Microsoft

$289.60 /

+3.42 (+1.20%)

Jefferies analyst Brent…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MSFT Microsoft
$289.60 /

+3.42 (+1.20%)

MSFT Microsoft
$289.60 /

+3.42 (+1.20%)

07/23/21 Barclays
Microsoft price target raised to $325 from $288 at Barclays
07/22/21 BofA
Microsoft price target raised to $325 from $305 at BofA
07/22/21 Cowen
Microsoft price target raised to $310 from $295 at Cowen
07/22/21 KeyBanc
Microsoft price target raised to $330 from $305 at KeyBanc
MSFT Microsoft
$289.60 /

+3.42 (+1.20%)

MSFT Microsoft
$289.60 /

+3.42 (+1.20%)

MSFT Microsoft
$289.60 /

+3.42 (+1.20%)

MSFT Microsoft
$289.60 /

+3.42 (+1.20%)

On The Fly
On the Fly: The Week in SPAC News » 08:32
07/25/21
07/25
08:32
07/25/21
08:32
DGNS

Dragoneer Growth Opportunities Corp. II

$9.95 /

-0.06 (-0.60%)

, CVT

Cvent

$36.00 /

+ (+0.00%)

, ZM

Zoom Video

$359.12 /

-2.39 (-0.66%)

, BTNB

Bridgetown 2 Holdings

$9.96 /

-0.05 (-0.50%)

, VELO

Velocity Acquisition

$9.84 /

+ (+0.00%)

, BBQG

BBQGuys

/

+

, VII

7GC & Co.

$9.70 /

+ (+0.00%)

, OCA

Omnichannel Acquisition

$9.90 /

+0.02 (+0.20%)

, KI

Kin Insurance

/

+

, PRTC

PureTech Health

$48.00 /

+ (+0.00%)

, CPSR

Capstar Special Purpose Acquisition Corp.

$9.83 /

+ (+0.00%)

, GLS

Gelesis

$10.80 /

+ (+0.00%)

, IIAC

Investindustrial Acquisition

$9.91 /

+0.01 (+0.10%)

, AHAC

Alpha Healthcare Acquisition

$9.99 /

+0.03 (+0.30%)

, BLNG

Belong Acquisition

$33.94 /

+ (+0.00%)

, PFTA

Portage Fintech Acquisition

/

+

, CLOE

Clover Leaf Capital

/

+

, CLAY

Chavant Capital Acquisition

$5.98 /

+ (+0.00%)

In SPAC news this week,…

ShowHide Related Items >><<
ZM Zoom Video
$359.12 /

-2.39 (-0.66%)

VELO Velocity Acquisition
$9.84 /

+ (+0.00%)

PRTC PureTech Health
$48.00 /

+ (+0.00%)

OCA Omnichannel Acquisition
$9.90 /

+0.02 (+0.20%)

IIAC Investindustrial Acquisition
$9.91 /

+0.01 (+0.10%)

DGNS Dragoneer Growth Opportunities Corp. II
$9.95 /

-0.06 (-0.60%)

BTNB Bridgetown 2 Holdings
$9.96 /

-0.05 (-0.50%)

AHAC Alpha Healthcare Acquisition
$9.99 /

+0.03 (+0.30%)

DGNS Dragoneer Growth Opportunities Corp. II
$9.95 /

-0.06 (-0.60%)

CVT Cvent
$36.00 /

+ (+0.00%)

ZM Zoom Video
$359.12 /

-2.39 (-0.66%)

07/20/21 Craig-Hallum
Five9 downgraded to Hold from Buy at Craig-Hallum
07/20/21 Canaccord
Five9 downgraded to Hold from Buy at Canaccord
07/19/21 Morgan Stanley
Five9 cut to Equal Weight at Morgan Stanley after Zoom Video deal
07/19/21 William Blair
Competitive concerns driving RingCentral lower 'overblown,' says William Blair
BTNB Bridgetown 2 Holdings
$9.96 /

-0.05 (-0.50%)

VELO Velocity Acquisition
$9.84 /

+ (+0.00%)

BBQG BBQGuys
/

+

VII 7GC & Co.
$9.70 /

+ (+0.00%)

OCA Omnichannel Acquisition
$9.90 /

+0.02 (+0.20%)

KI Kin Insurance
/

+

PRTC PureTech Health
$48.00 /

+ (+0.00%)

02/10/21 Piper Sandler
PureTech Health price target raised to $76 from $66 at Piper Sandler
01/15/21 SVB Leerink
PureTech Health initiated with an Outperform at SVB Leerink
11/17/20 Piper Sandler
PureTech Health initiated with an Overweight at Piper Sandler
CPSR Capstar Special Purpose Acquisition Corp.
$9.83 /

+ (+0.00%)

GLS Gelesis
$10.80 /

+ (+0.00%)

IIAC Investindustrial Acquisition
$9.91 /

+0.01 (+0.10%)

AHAC Alpha Healthcare Acquisition
$9.99 /

+0.03 (+0.30%)

07/20/21 Benchmark
Alpha Healthcare Acquisition initiated with a Buy at Benchmark
04/09/21 Lake Street
Lake Street starts Alpha Healthcare Acquisition at Buy ahead of Humacyte closing
04/09/21 Lake Street
Alpha Healthcare Acquisition initiated with a Buy at Lake Street
BLNG Belong Acquisition
$33.94 /

+ (+0.00%)

PFTA Portage Fintech Acquisition
/

+

CLOE Clover Leaf Capital
/

+

CLAY Chavant Capital Acquisition
$5.98 /

+ (+0.00%)

ZM Zoom Video
$359.12 /

-2.39 (-0.66%)

  • 13
    Jan
ZM Zoom Video
$359.12 /

-2.39 (-0.66%)

VII 7GC & Co.
$9.70 /

+ (+0.00%)

VELO Velocity Acquisition
$9.84 /

+ (+0.00%)

DGNS Dragoneer Growth Opportunities Corp. II
$9.95 /

-0.06 (-0.60%)

ZM Zoom Video
$359.12 /

-2.39 (-0.66%)

VII 7GC & Co.
$9.70 /

+ (+0.00%)

VELO Velocity Acquisition
$9.84 /

+ (+0.00%)

AHAC Alpha Healthcare Acquisition
$9.99 /

+0.03 (+0.30%)

ZM Zoom Video
$359.12 /

-2.39 (-0.66%)

BTNB Bridgetown 2 Holdings
$9.96 /

-0.05 (-0.50%)

AHAC Alpha Healthcare Acquisition
$9.99 /

+0.03 (+0.30%)

Periodicals
Stock of Ray-Ban sunglasses looking brighter, Barron's says » 08:41
07/24/21
07/24
08:41
07/24/21
08:41
ESLOY

EssilorLuxottica

$91.31 /

+0.836 (+0.92%)

Ray-Ban and Oakley…

Ray-Ban and Oakley eyewear maker EssilorLuxottica has resolved several years of post-merger turmoil, naming an insider as CEO, tasked with integrating the two businesses, Rupert Steiner writes in this week's edition of Barron's. This new phase smooths the way for the company to cut costs, introduce new products, and consider possible acquisitions, which could transform the business and further boost the stock, the author contends. Reference Link

ShowHide Related Items >><<
ESLOY EssilorLuxottica
$91.31 /

+0.836 (+0.92%)

ESLOY EssilorLuxottica
$91.31 /

+0.836 (+0.92%)

07/20/21 UBS
EssilorLuxottica price target raised to EUR 182 from EUR 170 at UBS
07/07/21 Berenberg
EssilorLuxottica price target raised to EUR 175 from EUR 150 at Berenberg
07/01/21 Societe Generale
EssilorLuxottica price target raised to EUR 148.70 from EUR 134 at Societe Generale
07/01/21 RBC Capital
EssilorLuxottica downgraded to Sector Perform from Outperform at RBC Capital
ESLOY EssilorLuxottica
$91.31 /

+0.836 (+0.92%)

Periodicals
Robinhood IPO coming soon, 'steer clear,' Barron's says » 08:38
07/24/21
07/24
08:38
07/24/21
08:38
HOOD

Robinhood

/

+

There will be no velvet…

There will be no velvet rope at Robinhood Markets' big debut on Thursday, with the company offering up to a third of its shares in its initial public offering to app users, Avi Salzman writes in this week's edition of Barron's. Robinhood is a truly transformational company, but its problem is the quality and sustainability of its revenue, the author contends. Robinhood is also highly dependent on cryptocurrency trading, another area now getting a close review by the SEC, the publication adds. Reference Link

ShowHide Related Items >><<
HOOD Robinhood
/

+

  • 29
    Jul
HOOD Robinhood
/

+

HOOD Robinhood
/

+

Periodicals
Netflix opens new front in streaming war with games, Barron's says » 08:35
07/24/21
07/24
08:35
07/24/21
08:35
NFLX

Netflix

$515.27 /

+3.62 (+0.71%)

Almost ignored amid last…

Almost ignored amid last week's torrent of earnings news was confirmation from Netflix that the streaming video service plans to jump into mobile gaming, Eric Savitz writes in this week's edition of Barron's. But the move has the potential to shake up the nascent streaming gaming market-and to resolve some of the biggest concerns about the future of Netflix, the author contends. The kicker is that Netflix is not going to charge anything extra for games, and it isn't going to include in-game ads or in-game purchases, either. This, in short, is a revenue-free upgrade. At least on the surface, the publication adds. Reference Link

ShowHide Related Items >><<
NFLX Netflix
$515.27 /

+3.62 (+0.71%)

NFLX Netflix
$515.27 /

+3.62 (+0.71%)

07/21/21 Evercore ISI
Evercore reiterates Outperform on Netflix after Q2 'clearing event'
07/21/21 Wedbush
Netflix Q3 guidance 'uninspiring,' games a misstep, says Wedbush
07/21/21 Credit Suisse
Netflix price target raised to $643 from $586 at Credit Suisse
07/21/21 UBS
Netflix Q2 likely the low point for sub growth, says UBS
NFLX Netflix
$515.27 /

+3.62 (+0.71%)

NFLX Netflix
$515.27 /

+3.62 (+0.71%)

NFLX Netflix
$515.27 /

+3.62 (+0.71%)

NFLX Netflix
$515.27 /

+3.62 (+0.71%)

Periodicals
KeyCorp, M&T Bank among bank stocks with yields above 3%, Barron's says » 08:33
07/24/21
07/24
08:33
07/24/21
08:33
CFG

Citizens Financial

$43.64 /

+0.16 (+0.37%)

, MTB

M&T Bank

$129.31 /

+0.36 (+0.28%)

, KEY

KeyCorp

$19.10 /

+0.095 (+0.50%)

, FITB

Fifth Third

$35.78 /

-0.2 (-0.56%)

This year's rally in…

This year's rally in bank stocks appears to have slowed to a sputter, but investors should stick around given banks' reliable dividends at a time when income investors lack compelling opportunities, Carleton English writes in this week's edition of Barron's. With yields so low, regional banks like Citizens Financial (CFG), M&T Bank (MTB), KeyCorp (KEY), and Fifth Third Bank (FITB) offer income investors steady payouts and the potential for capital appreciation, the author contends. Reference Link

ShowHide Related Items >><<
MTB M&T Bank
$129.31 /

+0.36 (+0.28%)

KEY KeyCorp
$19.10 /

+0.095 (+0.50%)

FITB Fifth Third
$35.78 /

-0.2 (-0.56%)

CFG Citizens Financial
$43.64 /

+0.16 (+0.37%)

CFG Citizens Financial
$43.64 /

+0.16 (+0.37%)

07/16/21 Citi
Citizens Financial assumed with a Neutral at Citi
07/06/21 Keefe Bruyette
Citizens Financial assumed with an Outperform at Keefe Bruyette
05/18/21 Compass Point
Citizens Financial price target raised to $55 from $51 at Compass Point
05/03/21 JPMorgan
Citizens Financial price target raised to $50 from $48 at JPMorgan
MTB M&T Bank
$129.31 /

+0.36 (+0.28%)

07/22/21 Wedbush
M&T Bank price target lowered to $158 from $171 at Wedbush
07/22/21 Wells Fargo
M&T Bank price target lowered to $155 from $168 at Wells Fargo
07/19/21 Odeon Capital
M&T Bank upgraded to Hold from Sell at Odeon Capital
07/16/21 Citi
M&T Bank assumed with a Neutral at Citi
KEY KeyCorp
$19.10 /

+0.095 (+0.50%)

07/19/21 Odeon Capital
KeyCorp downgraded to Hold from Buy at Odeon Capital
07/16/21 Citi
KeyCorp assumed with a Neutral at Citi
07/06/21 Keefe Bruyette
KeyCorp assumed with a Market Perform at Keefe Bruyette
04/29/21 Citi
KeyCorp price target raised to $24 from $20 at Citi
FITB Fifth Third
$35.78 /

-0.2 (-0.56%)

07/19/21 Odeon Capital
Fifth Third downgraded to Hold from Buy at Odeon Capital
07/16/21 Citi
Fifth Third assumed with a Neutral at Citi
07/06/21 Keefe Bruyette
Fifth Third assumed with a Market Perform at Keefe Bruyette
06/03/21 Baird
Fifth Third price target raised to $44 from $39 at Baird
MTB M&T Bank
$129.31 /

+0.36 (+0.28%)

KEY KeyCorp
$19.10 /

+0.095 (+0.50%)

FITB Fifth Third
$35.78 /

-0.2 (-0.56%)

CFG Citizens Financial
$43.64 /

+0.16 (+0.37%)

MTB M&T Bank
$129.31 /

+0.36 (+0.28%)

MTB M&T Bank
$129.31 /

+0.36 (+0.28%)

FITB Fifth Third
$35.78 /

-0.2 (-0.56%)

CFG Citizens Financial
$43.64 /

+0.16 (+0.37%)

CFG Citizens Financial
$43.64 /

+0.16 (+0.37%)

Periodicals
Tripadvisor the cheapest online travel stock, good time to buy, Barron's says » 08:30
07/24/21
07/24
08:30
07/24/21
08:30
TRIP

TripAdvisor

$36.27 /

+0.21 (+0.58%)

, BKNG

Booking Holdings

$2,200.62 /

+6.02 (+0.27%)

, EXPE

Expedia

$161.61 /

+1.56 (+0.97%)

Tripadvisor (TRIP), best…

Tripadvisor (TRIP), best known for online travel reviews, has struggled to make the most of its hundreds of millions of users, but that could soon change, Andrew Bary writes in this week's edition of Barron's. The company has started a new travel subscription service, Tripadvisor Plus, that offers discounted hotel rates and other benefits, which could rekindle interest in what has been online travel's also-ran to Booking Holdings (BKNG) and Expedia Group (EXPE), the author notes. Further, the publication points out that shares of Tripadvisor, now around $36, look inexpensive, having fallen from a March peak of $65 and trading for half of where they stood five years ago. Reference Link

ShowHide Related Items >><<
TRIP TripAdvisor
$36.27 /

+0.21 (+0.58%)

EXPE Expedia
$161.61 /

+1.56 (+0.97%)

BKNG Booking Holdings
$2,200.62 /

+6.02 (+0.27%)

TRIP TripAdvisor
$36.27 /

+0.21 (+0.58%)

06/16/21 Truist
TripAdvisor rolls out subscription product 'on schedule,' says Truist
06/14/21 Ascendiant
TripAdvisor price target raised to $54 from $50 at Ascendiant
05/10/21 Gordon Haskett
TripAdvisor unused convertible funds still 'on radar,' says Gordon Haskett
05/10/21 Credit Suisse
TripAdvisor price target raised to $37 from $31 at Credit Suisse
BKNG Booking Holdings
$2,200.62 /

+6.02 (+0.27%)

05/26/21 RBC Capital
Booking Holdings assumed with a Sector Perform at RBC Capital
05/07/21 Susquehanna
Booking Holdings price target lowered to $2850 from $3000 at Susquehanna
05/06/21 Credit Suisse
Booking Holdings price target lowered to $2,675 from $2,740 at Credit Suisse
05/06/21 Deutsche Bank
Booking Holdings price target raised to $2,665 from $2,600 at Deutsche Bank
EXPE Expedia
$161.61 /

+1.56 (+0.97%)

05/26/21 RBC Capital
Expedia assumed with a Sector Perform at RBC Capital
05/12/21 Citi
Expedia price target raised to $179 from $160 at Citi
05/07/21 BTIG
Expedia price target raised to $210 from $180 at BTIG
05/07/21 Credit Suisse
Expedia price target raised to $198 from $168 at Credit Suisse
TRIP TripAdvisor
$36.27 /

+0.21 (+0.58%)

EXPE Expedia
$161.61 /

+1.56 (+0.97%)

BKNG Booking Holdings
$2,200.62 /

+6.02 (+0.27%)

TRIP TripAdvisor
$36.27 /

+0.21 (+0.58%)

EXPE Expedia
$161.61 /

+1.56 (+0.97%)

TRIP TripAdvisor
$36.27 /

+0.21 (+0.58%)

EXPE Expedia
$161.61 /

+1.56 (+0.97%)

BKNG Booking Holdings
$2,200.62 /

+6.02 (+0.27%)

TRIP TripAdvisor
$36.27 /

+0.21 (+0.58%)

EXPE Expedia
$161.61 /

+1.56 (+0.97%)

Periodicals
Evoqua stock a bet on clean water, Barron's says » 08:25
07/24/21
07/24
08:25
07/24/21
08:25
AQUA

Evoqua Water

$32.80 /

+0.36 (+1.11%)

Water is an economic…

Water is an economic paradox. Everyone needs it, but it's often cheap because it's usually, though not always, plentiful, Al Root writes in this week's edition of Barron's. Good water stocks, however, aren't plentiful-which makes Evoqua Water Technologies, a water-treatment company, a good stock to tap into, the author contends. Reference Link

ShowHide Related Items >><<
AQUA Evoqua Water
$32.80 /

+0.36 (+1.11%)

AQUA Evoqua Water
$32.80 /

+0.36 (+1.11%)

07/07/21 Raymond James
Evoqua Water downgraded to Outperform from Strong Buy at Raymond James
07/07/21 Raymond James
Evoqua Water downgraded to Outperform from Strong Buy at Raymond James
06/23/21 Credit Suisse
Evoqua Water price target raised to $37 from $32 at Credit Suisse
06/16/21 RBC Capital
Evoqua Water price target raised to $38 from $34 at RBC Capital
AQUA Evoqua Water
$32.80 /

+0.36 (+1.11%)

  • 09
    Feb
  • 01
    Dec
  • 07
    Aug
AQUA Evoqua Water
$32.80 /

+0.36 (+1.11%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.